AR062482A1 - Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados - Google Patents
Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionadosInfo
- Publication number
- AR062482A1 AR062482A1 ARP070103727A ARP070103727A AR062482A1 AR 062482 A1 AR062482 A1 AR 062482A1 AR P070103727 A ARP070103727 A AR P070103727A AR P070103727 A ARP070103727 A AR P070103727A AR 062482 A1 AR062482 A1 AR 062482A1
- Authority
- AR
- Argentina
- Prior art keywords
- hepatitis
- rna
- hcv
- individual
- ns5b
- Prior art date
Links
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 7
- 238000012512 characterization method Methods 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 15
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 7
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 108060004795 Methyltransferase Proteins 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos para disminuir la frecuencia de aparicion, disminuir el nivel de resistencia y retardar la aparicion de una infeccion viral de hepatitis C resistente al tratamiento, mediante la administracion a un sujeto, ya sea en forma combinada o en serie, de un inhibidor de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C, por ejemplo, un benzofurano, tal como 5-ciclopropil-2-(4-fluorofenil)-6-[(2-hidroxietil)(metilsulfonil)amino]-N-metil-1-benzofuran-3-carboxamida (VHC-796), y al menos un agente anti-hepatitis C adicional, por ejemplo, un producto de ribavirina o un inmunomodulador, tal como un producto de interferon. Además se refiere a métodos para monitorear el curso de tratamiento de una infeccion viral de hepatitis C, métodos para monitorear y pronosticar una infeccion viral de hepatitis C, y métodos para identificar un individuo con menor probabilidad de responder a un tratamiento contra la hepatitis C viral. Estos métodos usan la secuencia y/o estructura de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C para identificar la aparicion de una infeccion viral de hepatitis C resistente al tratamiento, en particular una infeccion viral de hepatitis C resistente al tratamiento con benzofurano (por ejemplo, VHC-796). Reivindicacion 11: Un método para identificar un individuo con menor probabilidad de responder a un tratamiento contra la hepatitis C viral, que comprende: (a) determinar la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en una muestra del individuo en un primer punto temporal; y (b) determinar la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en una muestra del individuo en un segundo punto temporal, donde un cambio en la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en la muestra del individuo en el segundo punto temporal, en comparacion con la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C del individuo en el primer punto temporal, indica una menor probabilidad de que el individuo responda a un tratamiento contra la hepatitis C viral.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84035306P | 2006-08-25 | 2006-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062482A1 true AR062482A1 (es) | 2008-11-12 |
Family
ID=39022157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103727A AR062482A1 (es) | 2006-08-25 | 2007-08-22 | Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080182895A1 (es) |
| AR (1) | AR062482A1 (es) |
| AU (1) | AU2007286754A1 (es) |
| BR (1) | BRPI0715714A2 (es) |
| CA (1) | CA2659461A1 (es) |
| CL (1) | CL2007002447A1 (es) |
| PE (1) | PE20081215A1 (es) |
| TW (1) | TW200816990A (es) |
| WO (1) | WO2008024763A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0516356A (pt) * | 2004-10-18 | 2008-09-02 | Globeimmune Inc | terapia à base de levedura para infecções crÈnicas da hepatite c |
| EP2101173A1 (en) * | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
| FR2933094A1 (fr) * | 2008-06-26 | 2010-01-01 | Univ Joseph Fourier | Mutations dans la proteine ns5b du vhc. |
| EP2331125A4 (en) * | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| ES2529143B1 (es) | 2011-10-21 | 2015-10-26 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE102014219858B4 (de) | 2014-09-30 | 2021-09-23 | Aktiebolaget Skf | Kreuzgelenk |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
| GB201704386D0 (en) * | 2017-03-20 | 2017-05-03 | Univ London Queen Mary | Method for identification of sofosbuvir resistant patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018231A1 (en) * | 1998-09-25 | 2000-04-06 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| DE10030139A1 (de) * | 2000-06-20 | 2002-01-10 | Cmi Ag | Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae |
| IL153670A0 (en) * | 2000-07-21 | 2003-07-06 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| CA2425513A1 (en) * | 2000-10-25 | 2002-06-20 | Vincent Agnello | Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| CA2429352A1 (en) * | 2000-12-15 | 2002-06-20 | Lieven Stuyver | Antiviral agents for treatment of flaviviridae infections |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| TW200400963A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| TW200400818A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
| CA2489552A1 (en) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| US7265152B2 (en) * | 2002-11-01 | 2007-09-04 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| AU2003298658A1 (en) * | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| CN100347184C (zh) * | 2003-01-07 | 2007-11-07 | 凯敏制药欧洲股份有限公司 | 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物 |
| CN1980678A (zh) * | 2003-03-28 | 2007-06-13 | 法莫赛特股份有限公司 | 治疗黄病毒感染的化合物 |
| WO2005000308A2 (en) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
| CN1852915A (zh) * | 2003-07-25 | 2006-10-25 | 艾登尼科斯（开曼）有限公司 | 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物 |
| TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| JP2005202801A (ja) * | 2004-01-16 | 2005-07-28 | Sharp Corp | 表示装置 |
| WO2006000922A2 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| US20060035848A1 (en) * | 2004-08-09 | 2006-02-16 | Zymetx, Inc. | Broad-spectrum inhibitor of viruses in the Flaviviridae family |
| TWM262874U (en) * | 2004-08-10 | 2005-04-21 | Starlink Electronics Corp | LGA terminal structure with changed circuit |
| CN101035528A (zh) * | 2004-09-23 | 2007-09-12 | 惠氏公司 | 治疗丙型肝炎病毒感染的咔唑和环戊二烯并吲哚衍生物 |
| WO2007041632A2 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
| EP1948137A2 (en) * | 2005-11-10 | 2008-07-30 | Wyeth a Corporation of the State of Delaware | Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-(2-hydroxyethyl)(methylsulfonyl) amino-n-methyl-1-benzofuran-3-carboxamide and method of making same |
| WO2007059421A2 (en) * | 2005-11-10 | 2007-05-24 | Wyeth | Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same |
| AR059430A1 (es) * | 2006-02-09 | 2008-04-09 | Schering Corp | Novedosas combinaciones y metodos de inhibidores del vhc |
| TW200815384A (en) * | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
-
2007
- 2007-08-21 AU AU2007286754A patent/AU2007286754A1/en not_active Abandoned
- 2007-08-21 US US11/842,312 patent/US20080182895A1/en not_active Abandoned
- 2007-08-21 CA CA002659461A patent/CA2659461A1/en not_active Abandoned
- 2007-08-21 WO PCT/US2007/076408 patent/WO2008024763A2/en active Application Filing
- 2007-08-21 BR BRPI0715714-2A2A patent/BRPI0715714A2/pt not_active Application Discontinuation
- 2007-08-22 CL CL200702447A patent/CL2007002447A1/es unknown
- 2007-08-22 TW TW096131070A patent/TW200816990A/zh unknown
- 2007-08-22 AR ARP070103727A patent/AR062482A1/es unknown
- 2007-08-22 PE PE2007001141A patent/PE20081215A1/es not_active Application Discontinuation
-
2009
- 2009-06-29 US US12/493,736 patent/US20100028922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007286754A1 (en) | 2008-02-28 |
| PE20081215A1 (es) | 2008-10-22 |
| TW200816990A (en) | 2008-04-16 |
| US20080182895A1 (en) | 2008-07-31 |
| CA2659461A1 (en) | 2008-02-28 |
| CL2007002447A1 (es) | 2008-03-14 |
| WO2008024763A2 (en) | 2008-02-28 |
| US20100028922A1 (en) | 2010-02-04 |
| WO2008024763A3 (en) | 2008-12-24 |
| BRPI0715714A2 (pt) | 2014-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062482A1 (es) | Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados | |
| Dietz et al. | Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients | |
| CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
| WO2011123645A3 (en) | Nucleoside phosphoramidates | |
| Wang et al. | Influenza A virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins | |
| MX347871B (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. | |
| Saghazadeh et al. | Implications of Toll-like receptors in Ebola infection | |
| ATE468363T1 (de) | Verfahren zur behandlung von oberflächen | |
| Testoni et al. | Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes | |
| RU2012145776A (ru) | Прогнозирование раннего вирусологического ответа при лечении заражения вирусом гепатита с | |
| Yang et al. | Immunopathogenesis of different emerging viral infections: evasion, fatal mechanism, and prevention | |
| Wong et al. | Evaluating antibody mediated protection against Alpha, Beta, and Delta SARS-CoV-2 variants of concern in K18-hACE2 transgenic mice | |
| RU2014124032A (ru) | Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с | |
| Eltahla et al. | Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders | |
| WO2008045017A3 (en) | Sars and ebola inhibitors and use thereof, and methods for their discovery | |
| NZ599373A (en) | Biomarkers for predicting rapid response to hcv treatment | |
| WO2018075633A3 (en) | Compositions and methods for detecting or quantifying hepatitis c virus | |
| Vilcek et al. | Molecular characterization of border disease virus strain Aveyron | |
| WO2014146048A3 (en) | Methods for determining viral sensitivity to viral inhibitors | |
| Kuri et al. | Interferon interplay helps tissue cells to cope with SARS-coronavirus infection | |
| WO2009021121A3 (en) | Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto | |
| Tavana et al. | p53 and DNA methylation suppress the TRAIN to cell death | |
| WO2007111628A3 (en) | Mxa as an antiviral drug and as a target for identification of antiviral drugs for dna virus infections | |
| Shrivastava et al. | Hepatitis C Virus Infection, Autophagy, and Innate Immune Response | |
| Masyeni1a et al. | Expression of four cytokine/chemokine genes in peripheral blood mononuclear cells infected with dengue virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |